Is Abbott Laboratories Better Than Johnson & Johnson For Your Dividend Portfolio?

In 1886, Johnson & Johnson (JNJ) was founded. Two years later, Abbott Laboratories (ABT) was founded. Over the last 128 years, Johnson & Johnson has grown to become the largest publicly traded health care company in the world, with a market cap of nearly $300 billion. Abbott Laboratories has grown immensely as well, and has a market capitalization of over $60 billion. If you include the value of the recently spun-off AbbVie (ABBV), the combined company would be worth about $150 billion.

The 8 Rules of Dividend Investing ranks Abbott Laboratories as a Top 10 stock due to its strong growth rate and low volatility. Johnson & Johnson ranks as the 28th highest stock gaining ground because of its extremely low volatility, which is partially offset by the company's relatively low revenue per share growth rate over the last 10 years.

Source: Seeking Alpha

Related Articles:
- 6 Healthcare Stocks With Growing Dividends Yielding In Excess of 2%
- Why We Are Dividend Growth Investors
- 6 Dividend Growth Stocks With Very Little Debt
- What Determines A Dividend Stock's Yield
- Warren Buffett's Secret To 50% Returns